Literature DB >> 19231345

Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation.

Madan Sharma1, Celina Yong, David Majure, Christian Zellner, John P Roberts, Nathan M Bass, Thomas A Ports, Yerem Yeghiazarians, Gabriel Gregoratos, Andrew J Boyle.   

Abstract

Patients with end-stage liver disease (ESLD) are predisposed to bleeding complications due to thrombocytopenia, reduced synthesis of coagulation factors, and increased fibrinolytic activity. The exact incidence of vascular access site and bleeding complications related to cardiac catheterization in this group remains unknown. Eighty-eight consecutive patients with ESLD who underwent left-sided cardiac catheterization from August 2004 to February 2007 were identified. Eighty-one patients without known liver disease matched for age, gender, and body mass index who underwent left-sided cardiac catheterization during the same period were chosen as the control group. Vascular complications were defined as hematoma >5 cm, pseudoaneurysm, arteriovenous fistula, or retroperitoneal bleeding. Patients with ESLD had lower baseline mean hematocrit (32.3 +/- 6.0% vs 39.2 +/- 6.2%, p <0.001) and mean platelet count (90.1 +/- 66.3 vs 236.1 +/- 77.1 x 10(9)/L, p <0.001) compared with controls. They also had higher mean serum creatinine (1.9 +/- 1.7 vs 1.2 +/- 0.8 mg/dl, p = 0.002) and mean international normalized ratio (1.6 +/- 0.7 vs 1.1 +/- 0.2, p <0.001). There were more complicated pseudoaneurysms in the patients with liver failure (5.7% [5 of 88]), compared with 0% in controls (p = 0.029). Patients with ESLD had lower starting hemoglobin levels and greater reductions in hemoglobin after cardiac catheterization, resulting in greater need for packed red blood cell transfusion (16% vs 4%, p = 0.008), fresh frozen plasma (51.7% vs 1.2%, p <0.001), and platelet transfusions (48.3% vs 1.2%, p <0.001). Major bleeding was higher in the ESLD group (14.8% vs 3.7%, p = 0.014), driven mainly by the need for blood transfusion. In conclusion, despite severe coagulopathy, left-sided cardiac catheterization may be performed safely in this patient population, with correction of coagulopathy and meticulous attention to procedural technique.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231345     DOI: 10.1016/j.amjcard.2008.10.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Trans-radial versus trans-femoral access in patients with end-stage liver disease undergoing cardiac catheterization.

Authors:  Kent Feng; Vipul Gupta; Enrique Terrazas; Yerem Yeghiazarians; Thomas Ports; Gabriel Gregoratos; Mehdi Tavakol; John Paul Roberts; Andrew Boyle
Journal:  Am J Cardiovasc Dis       Date:  2014-10-11

2.  Usefulness of international normalized ratio to predict bleeding complications in patients with end-stage liver disease who undergo cardiac catheterization.

Authors:  Jacob C Townsend; Richard Heard; Eric R Powers; Adrian Reuben
Journal:  Am J Cardiol       Date:  2012-06-22       Impact factor: 2.778

Review 3.  CON: Noninvasive Imaging Is the Preferred Strategy for Cardiovascular Risk Stratification in This Patient.

Authors:  Shravan Dave; Abbey Barnard; Michel Mendler
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 4.  Perioperative Cardiovascular Evaluation for Orthotopic Liver Transplantation.

Authors:  Robert J Donovan; Calvin Choi; Asghar Ali; Douglas M Heuman; Michael Fuchs; Anthony A Bavry; Ion S Jovin
Journal:  Dig Dis Sci       Date:  2016-11-09       Impact factor: 3.199

Review 5.  Role of cardiovascular intervention as a bridge to liver transplantation.

Authors:  Zankhana Raval; Matthew E Harinstein; James D Flaherty
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 6.  Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?

Authors:  Narendra S Choudhary; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

7.  Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.

Authors:  Jennifer B Miller; Esteban J Figueroa; Rebecca M Haug; Neeral L Shah
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-06

8.  Use of Computed Tomography Coronary Calcium Score for Coronary Artery Disease Risk Stratification During Liver Transplant Evaluation.

Authors:  Sabha Bhatti; Blanca Lizaola-Mayo; Mohammad Al-Shoha; Mauricio Garcia-Saenz-de-Sicilia; Fuad Habash; Karam Ayoub; Michael Karr; Zubair Ahmed; Daniel Borja-Cacho; Andres Duarte-Rojo
Journal:  J Clin Exp Hepatol       Date:  2021-08-21

9.  Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations.

Authors:  Lisa B VanWagner; Matthew E Harinstein; James R Runo; Christopher Darling; Marina Serper; Shelley Hall; Jon A Kobashigawa; Laura L Hammel
Journal:  Am J Transplant       Date:  2017-11-18       Impact factor: 8.086

Review 10.  Risk of Bleeding in End-Stage Liver Disease Patients Undergoing Cardiac Catheterization.

Authors:  Ahmed M Mahmoud; Islam Y Elgendy; Calvin Y Choi; Anthony A Bavry
Journal:  Tex Heart Inst J       Date:  2015-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.